Cerebellar Transcranial Alternating Current Stimulation (tACS) to Modulate Parkinson's Disease Tremor
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · May 19, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help people with Parkinson's disease (PD) manage their hand tremors, which can be difficult to control with traditional treatments. The researchers are testing a method called transcranial alternating current stimulation (tACS), which is a non-invasive technique that uses gentle electrical currents to stimulate the brain. What makes this study unique is that the stimulation is synchronized with the patient's own tremor, potentially providing better relief.
To participate in this trial, individuals must be between the ages of 65 and 74 and have a clinical diagnosis of Parkinson's disease, showing moderate to severe hand tremors. Those interested will need to give written consent and should not have other serious neurological or psychiatric conditions, heart pacemakers, or metal implants. The trial is currently recruiting participants, and those who join can expect to receive this innovative treatment while helping researchers understand its effectiveness in reducing tremors associated with Parkinson’s disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of Parkinson's disease based on UK Brain Bank criteria
- • Patient exhibiting moderate to severe hand tremor
- • Provision written informed consent by the patient
- Exclusion Criteria:
- • History of other neurological disorders such as vascular malformations, ischemic or haemorrhagic stroke, cerebral neoplasia, epilepsy, or major psychiatric illness
- • Existence of heart pacemaker or metal implants in the body
- • Pregnancy
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported